Results 161 to 170 of about 25,748 (208)
Fuzheng Huayu formula ameliorates chronic cholestatic liver injury by upregulating PPARa in mice. [PDF]
Chin MedZhang Z +10 more
europepmc +1 more source
Different aspects of pharmacological heart failure treatment. [PDF]
Eur Heart J Cardiovasc PharmacotherAgewall S.
europepmc +1 more source
Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases. [PDF]
Front PharmacolWatanabe S +4 more
europepmc +1 more source
Molecular Mechanisms and Clinical Evidence Supporting the Four Pillars of Therapy in Diabetic Kidney Disease: Emerging Therapeutic Perspectives. [PDF]
Int J Mol SciYanai H +3 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Acta Crystallographica Section C Crystal Structure Communications, 2005
Unlike the related fenofibrate molecule [Henry, Zhang, Gao & Bruckner (2003). Acta Cryst. E59, o699-o700], fenofibric acid {systematic name: 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid}, C17H15ClO4, contains a carboxylic acid moiety instead of an ester moiety. This polar moiety plays an important role in the formation of a rare acid-to-ketone
Nigam P, Rath +2 more
openaire +2 more sources
Unlike the related fenofibrate molecule [Henry, Zhang, Gao & Bruckner (2003). Acta Cryst. E59, o699-o700], fenofibric acid {systematic name: 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid}, C17H15ClO4, contains a carboxylic acid moiety instead of an ester moiety. This polar moiety plays an important role in the formation of a rare acid-to-ketone
Nigam P, Rath +2 more
openaire +2 more sources
Atherosclerosis, 1994
Rationale and development of a new fenofibrate formulation is described. A lower dispersion of particles size and thereby a better absorption rate leads to a decrease of the daily dose and provides a better control of the amount absorbed. Improved reproducibility of the pharmacological and therapeutic effect is expected.
A, Munoz, J P, Guichard, P, Reginault
openaire +2 more sources
Rationale and development of a new fenofibrate formulation is described. A lower dispersion of particles size and thereby a better absorption rate leads to a decrease of the daily dose and provides a better control of the amount absorbed. Improved reproducibility of the pharmacological and therapeutic effect is expected.
A, Munoz, J P, Guichard, P, Reginault
openaire +2 more sources
Cardiovascular Drug Reviews, 2002
ABSTRACTFenofibrate is a fibric acid derivative that has been marketed since the mid‐1970's (1998 in the United States). Its active metabolite, fenofibric acid, is responsible for the primary pharmacodynamic effects of the drug: reductions in total plasma cholesterol, lowdensity lipoprotein cholesterol, triglycerides, and very low‐density lipoprotein ...
openaire +2 more sources
ABSTRACTFenofibrate is a fibric acid derivative that has been marketed since the mid‐1970's (1998 in the United States). Its active metabolite, fenofibric acid, is responsible for the primary pharmacodynamic effects of the drug: reductions in total plasma cholesterol, lowdensity lipoprotein cholesterol, triglycerides, and very low‐density lipoprotein ...
openaire +2 more sources
The American Journal of Medicine, 1987
This discussion outlines the major aspects of the human pharmacology of fenofibrate, a hypolipidemic agent. In view of its short half-life, efficient absorption, and elimination, fenofibrate would not appear to accumulate in either plasma or tissues. It is extensively absorbed only in the presence of food and is transported through the bloodstream by ...
openaire +2 more sources
This discussion outlines the major aspects of the human pharmacology of fenofibrate, a hypolipidemic agent. In view of its short half-life, efficient absorption, and elimination, fenofibrate would not appear to accumulate in either plasma or tissues. It is extensively absorbed only in the presence of food and is transported through the bloodstream by ...
openaire +2 more sources